Logo image of HSCS

HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

NASDAQ:HSCS - Nasdaq - US42254E3027 - Common Stock - Currency: USD

3.56  -0.02 (-0.56%)

Fundamental Rating

3

HSCS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. HSCS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSCS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HSCS has reported negative net income.
HSCS had a negative operating cash flow in the past year.
In the past 5 years HSCS always reported negative net income.
HSCS had a negative operating cash flow in each of the past 5 years.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

The Return On Assets of HSCS (-115.80%) is worse than 85.64% of its industry peers.
HSCS's Return On Equity of -369.69% is on the low side compared to the rest of the industry. HSCS is outperformed by 86.17% of its industry peers.
Industry RankSector Rank
ROA -115.8%
ROE -369.69%
ROIC N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 67.20%, HSCS is in the better half of the industry, outperforming 73.94% of the companies in the same industry.
HSCS's Gross Margin has improved in the last couple of years.
HSCS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.91%
GM growth 5YN/A
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

5

2. Health

2.1 Basic Checks

HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HSCS has been reduced compared to 1 year ago.
Compared to 1 year ago, HSCS has an improved debt to assets ratio.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -21.21, we must say that HSCS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -21.21, HSCS is not doing good in the industry: 90.96% of the companies in the same industry are doing better.
HSCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.21
ROIC/WACCN/A
WACC8.31%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M -6M

2.3 Liquidity

HSCS has a Current Ratio of 1.02. This is a normal value and indicates that HSCS is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.02, HSCS is not doing good in the industry: 89.36% of the companies in the same industry are doing better.
A Quick Ratio of 0.83 indicates that HSCS may have some problems paying its short term obligations.
HSCS has a Quick ratio of 0.83. This is amonst the worse of the industry: HSCS underperforms 84.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.83
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.40% over the past year.
HSCS shows a strong growth in Revenue. In the last year, the Revenue has grown by 257.69%.
Measured over the past years, HSCS shows a very negative growth in Revenue. The Revenue has been decreasing by -10.10% on average per year.
EPS 1Y (TTM)50.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.33%
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

HSCS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.81% yearly.
Based on estimates for the next years, HSCS will show a very strong growth in Revenue. The Revenue will grow by 358.08% on average per year.
EPS Next Y80.6%
EPS Next 2Y36.08%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y289.58%
Revenue Next 3Y358.08%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2026 2027 1M 2M 3M 4M 5M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSCS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

A more expensive valuation may be justified as HSCS's earnings are expected to grow with 24.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.08%
EPS Next 3Y24.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HSCS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEARTSCIENCES INC

NASDAQ:HSCS (6/9/2025, 11:21:40 AM)

3.56

-0.02 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)N/A N/A
Inst Owners1.16%
Inst Owner Change1267.52%
Ins Owners4.96%
Ins Owner Change0%
Market Cap3.84M
Analysts82.5
Price Target13.26 (272.47%)
Short Float %0.97%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.05%
Min EPS beat(2)-6.31%
Max EPS beat(2)8.42%
EPS beat(4)1
Avg EPS beat(4)-107.45%
Min EPS beat(4)-426.89%
Max EPS beat(4)8.42%
EPS beat(8)3
Avg EPS beat(8)-53.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.35%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 206.71
P/FCF N/A
P/OCF N/A
P/B 2.15
P/tB 21.58
EV/EBITDA N/A
EPS(TTM)-26.29
EYN/A
EPS(NY)-7.54
Fwd EYN/A
FCF(TTM)-6.94
FCFYN/A
OCF(TTM)-6.81
OCFYN/A
SpS0.02
BVpS1.65
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.8%
ROE -369.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.2%
FCFM N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.91%
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 335.88%
Cap/Sales 709.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 0.83
Altman-Z -21.21
F-Score3
WACC8.31%
ROIC/WACCN/A
Cap/Depr(3y)174.76%
Cap/Depr(5y)108.85%
Cap/Sales(3y)346.26%
Cap/Sales(5y)211.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.33%
EPS Next Y80.6%
EPS Next 2Y36.08%
EPS Next 3Y24.81%
EPS Next 5YN/A
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y289.58%
Revenue Next 3Y358.08%
Revenue Next 5YN/A
EBIT growth 1Y-3.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.72%
EBIT Next 3Y-6.59%
EBIT Next 5YN/A
FCF growth 1Y-46.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.17%
OCF growth 3YN/A
OCF growth 5YN/A